GNH USA

Europe — EMA

Nitisinone Dipharma

GNH USA supplies Nitisinone Dipharma (Nitisinone), a 4‑hydroxyphenylpyruvate dioxygenase inhibitor for hereditary tyrosinemia type I.

Nitisinone

Request sourcing

1
Pack/s

What is Nitisinone?

Nitisinone, the active ingredient in Nitisinone Dipharma, is a 4‑hydroxyphenylpyruvate dioxygenase inhibitor presented as an oral dosage form for oral use. It treats hereditary tyrosinemia type I in patients with this metabolic disorder.

GNH USA supplies Nitisinone Dipharma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, pharmacies and clinics worldwide.

What is Nitisinone used for?

Nitisinone is used to manage disorders of the tyrosine degradation pathway, primarily hereditary tyrosinemia type I.

- Hereditary tyrosinemia type I (pediatric): prevents accumulation of toxic metabolites and reduces risk of liver failure. - Hereditary tyrosinemia type I (adult): improves metabolic control and supports long‑term survival. - Hereditary tyrosinemia type I (pre‑transplant): stabilises disease to allow safe liver transplantation.

What are the side effects of Nitisinone?

Adverse reactions to Nitisinone may vary in frequency and severity.

Common Side Effects: - Headache: mild to moderate intensity. - Nausea: occasional gastrointestinal upset. - Skin rash: erythematous or pruritic lesions. - Fatigue: generalized tiredness. - Abdominal pain: discomfort in the stomach area.

Serious or Rare Side Effects: - Hepatic failure: signs of liver dysfunction. - Severe anemia: marked reduction in hemoglobin. - Neutropenia: low neutrophil count increasing infection risk. - Hypersensitivity reactions: including angioedema or anaphylaxis. - Peripheral neuropathy: numbness or tingling in extremities.

What precautions apply to Nitisinone?

Before initiating therapy, clinicians should consider several safety measures.

- Monitor liver function: assess transaminases and bilirubin regularly. - Monitor blood counts: watch for anemia or neutropenia. - Assess renal function: adjust use if significant impairment exists. - Avoid in patients with known hypersensitivity to nitisinone or excipients. - Use caution during pregnancy: risk–benefit evaluation required. - Store at room temperature: keep in the original container, protect from moisture and light.

What does Nitisinone interact with?

Nitisinone may interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid): - Concurrent HPPD inhibitors: additive inhibition may increase toxicity. - Strong CYP3A4 inducers (e.g., rifampin): may markedly reduce nitisinone plasma levels.

Moderate Interactions (Monitor Closely): - Warfarin: potential alteration of anticoagulant effect. - Acetaminophen: increased risk of hepatic stress. - Oral contraceptives: possible reduction in contraceptive efficacy.

Frequently asked questions

What is Nitisinone Dipharma used for?+
Nitisinone Dipharma is prescribed for the treatment of hereditary tyrosinemia type I, a rare inherited metabolic disorder that leads to the buildup of toxic tyrosine metabolites. By controlling these metabolites, the medication helps prevent liver damage, renal complications, and other serious health issues associated with the disease.
How does nitisinone work?+
Nitisinone works by inhibiting the enzyme 4‑hydroxyphenylpyruvate dioxygenase (HPPD), which is essential in the breakdown of the amino acid tyrosine. Blocking HPPD stops the formation of downstream toxic compounds such as fumarylacetoacetate and succinylacetone, thereby reducing the metabolic toxicity that drives the clinical manifestations of hereditary tyrosinemia type I.
What is the usual dose of Nitisinone Dipharma?+
The dosage of Nitisinone Dipharma is individualized and must be determined by a qualified prescriber. The treating physician will consider the patient’s age, weight, disease severity, and laboratory parameters to set an appropriate dosing regimen and adjust it as needed during therapy.
Is Nitisinone Dipharma safe during pregnancy or breastfeeding?+
Safety data for nitisinone in pregnancy and lactation are limited. The drug should only be used if the potential benefit justifies the possible risk to the fetus or infant. Healthcare providers typically evaluate each case carefully and may recommend alternative management strategies for pregnant or nursing patients.
How do I order Nitisinone Dipharma from GNH USA?+
To place an order, submit an enquiry on the product page at gnh-usa.com, specifying the required quantity. GNH USA works with hospitals, pharmacies, and procurement teams worldwide, and will request verification of trade or institutional credentials. After confirmation, the team provides pricing, availability, shipping details (including any cold‑chain requirements), and assists with import documentation.
How does Nitisinone compare with the main alternative treatment?+
The primary alternative for hereditary tyrosinemia type I is liver transplantation, which addresses the underlying metabolic defect but carries surgical risks and long‑term immunosuppression. Nitisinone offers a non‑surgical, disease‑modifying approach that can stabilize patients and, in many cases, delay or avoid the need for transplantation. Choice of therapy depends on disease stage, patient condition, and specialist recommendation.
What are the storage and handling requirements for Nitisinone Dipharma?+
Nitisinone Dipharma should be stored at room temperature, below 25 °C, in its original packaging to protect it from moisture and light. Keep the product out of reach of children and avoid exposing it to extreme temperatures or humidity, which could affect its stability.
How is Nitisinone Dipharma given or administered?+
The medication is administered orally, usually as a tablet or capsule, and should be taken with water. It can be taken with or without food, but consistency with regard to meals helps maintain stable drug levels. Patients should follow the prescribing physician’s instructions regarding timing and any necessary dietary considerations.
What are the most serious risks to watch for while taking Nitisinone Dipharma?+
Serious adverse events include hepatic failure, severe anemia, neutropenia, hypersensitivity reactions (such as angioedema or anaphylaxis), and peripheral neuropathy. Patients should be educated to report signs of liver dysfunction (jaundice, dark urine), unexplained fatigue, fever, or any allergic symptoms promptly to their healthcare provider.
Who should not use Nitisinone Dipharma?+
Nitisinone Dipharma is contraindicated in individuals with known hypersensitivity to nitisinone or any of its excipients. It should also be avoided in patients with severe hepatic impairment where the drug’s metabolism could be compromised, and used with caution in those with significant renal dysfunction. A prescriber must evaluate each patient’s medical history before initiating therapy.
Information provided on this page is for educational use by procurement and clinical professionals. Always consult a licensed healthcare provider for medical advice and prescribing decisions. GNH USA supplies this product subject to applicable regulatory and licensing requirements.
Send a sourcing enquiry for this product →

Product details

Drug
Nitisinone
Route
Oral Use
Manufacturer
Dipharma Arzneimittel Gmbh
Origin
EU

Related products

Nitisinone 2 mg/1

Nitisinone 2 mg/1

Nitisinone · 2 mg

Nitisinone
CAPSULE
Endo USA, Inc.
USA
Nitisinone 5 mg/1

Nitisinone 5 mg/1

Nitisinone · 5 mg

Nitisinone
CAPSULE
Endo USA, Inc.
USA
Nitisinone 10 mg/1

Nitisinone 10 mg/1

Nitisinone · 10 mg

Nitisinone
CAPSULE
Endo USA, Inc.
USA
Mdk-Nitisinone 2 mg

Mdk-Nitisinone 2 mg

Nitisinone · 2 MG

Mdk-Nitisinone
CAPSULE
MENDELIKABS INC
CANADA